[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601310":3},{"organization":4,"outcomesModule":7,"designInfo":34,"detailedDescription":40,"studyPopulation":33,"armGroups":41,"interventions":48,"overallOfficials":33,"centralContacts":54,"locations":60,"responsibleParty":76,"collaborators":80,"id":86,"slug":33,"hasResults":87,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":33,"eligibilityCriteria":91,"healthyVolunteers":87,"sex":92,"minAge":93,"maxAge":94,"enrollmentInfo":95,"targetDuration":33,"studyType":98,"phases":99,"briefSummary":100,"conditions":101,"keywords":103,"overallStatus":110,"whyStopped":33,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},{"fullName":5,"class":6},"Henan Institute of Cardiovascular Epidemiology","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":33},[9,13],{"measure":10,"description":11,"timeFrame":12},"Rate of Achieving Target Office Systolic Blood Pressure at 180 Days","The percentage of subjects whose office systolic blood pressure (SBP) is less than 140mmHg at the 180-day post-procedure follow-up. Office blood pressure will be measured in a resting state according to a standardized procedure.","180 days post-procedure",{"measure":14,"description":15,"timeFrame":12},"Change From Baseline in Antihypertensive Medication Composite Score at 180 Days","The change from baseline in a composite score reflecting the type and dose of antihypertensive medication required to achieve a target office SBP of \\\u003C140mmHg. The score is calculated as (number of drug classes) multiplied by (the sum of the doses), where a standard daily dose is defined as 1, a half dose is 0.5, and a double dose is 2. The change is calculated as the baseline score minus the 180-day score.",[17,21,25,29],{"measure":18,"description":19,"timeFrame":20},"Procedural Success Rate","The percentage of procedures where the renal artery radiofrequency ablation clamp is successfully positioned and the denervation procedure is completed without related complications, which include renal artery perforation and renal artery embolism.","Intra-procedural",{"measure":22,"description":23,"timeFrame":24},"Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure at 180 Days","The reduction in mean 24-hour ambulatory systolic blood pressure (SBP) at 180 days post-procedure compared to the baseline measurement.","Baseline and 180 days post-procedure",{"measure":26,"description":27,"timeFrame":28},"Incidence of Major Adverse Events (MAE)","The percentage of subjects experiencing one or more Major Adverse Events. MAEs include all-cause mortality, new myocardial infarction, major bleeding, end-stage renal disease, major embolic events causing end-organ damage, renal artery re-intervention, renal artery perforation or dissection, vascular complications requiring intervention, hospitalization for hypertensive crisis, new stroke, or new-onset renal artery stenosis (≥70%).","Up to 180 days post-procedure",{"measure":30,"description":31,"timeFrame":32},"Incidence of Laparoscopic Surgery-Related Adverse Events","The percentage of subjects experiencing adverse events related to the laparoscopic procedure. These include pneumoperitoneum-related complications (e.g., gas embolism, pneumothorax), injury to major abdominal or retroperitoneal vessels, visceral injury (bowel, bladder, liver, spleen), or ureteral injury.","Up to 30 days post-procedure",null,{"allocation":35,"interventionModel":36,"interventionModelDescription":33,"primaryPurpose":37,"observationalModel":33,"timePerspective":33,"maskingInfo":38},"NA","SINGLE_GROUP","TREATMENT",{"masking":39,"maskingDescription":33,"whoMasked":33},"NONE","Rationale: Hypertension is a leading risk factor for cardiovascular disease. A significant portion of patients have refractory hypertension, where blood pressure remains elevated despite the use of multiple antihypertensive medications. The renal sympathetic nervous system plays a crucial role in blood pressure regulation, and its overactivity is a key factor in hypertension. Renal Denervation (RDN) is a device-based therapy designed to lower blood pressure by ablating these nerves. While most existing RDN systems use an endovascular (inside the artery) approach, this method carries potential risks such as endothelial damage, thrombosis, or renal artery stenosis.\n\nStudy Objective and Design: This is a prospective, single-center, single-arm, first-in-man (FIM) clinical study designed to provide a preliminary evaluation of the safety and efficacy of a novel laparoscopic adventitial RDN system for treating refractory or drug-intolerant hypertension. A total of 10 subjects will be enrolled. The study aims to gather initial feasibility and safety data to support the design of future, larger clinical trials.\n\nIntervention: The investigational procedure is a laparoscopic renal artery adventitial RDN. This technique involves placing a Renal Artery Radiofrequency Ablation Clamp around the external surface (adventitia) of the main renal arteries. A compatible radiofrequency generator delivers energy to the clamp's electrodes, creating targeted lesions to ablate the sympathetic nerves while preserving the integrity of the arterial wall.\n\nMethodology: Potential subjects will be screened for eligibility. Qualified candidates will enter a 28-day run-in period where they will be treated with a standardized, fixed-dose combination of at least three antihypertensive drugs, including a diuretic. This period is to confirm refractory status and assess medication adherence, which is confirmed via urine analysis. Subjects who still meet the blood pressure criteria after the run-in period will undergo the laparoscopic RDN procedure. Post-procedure, subjects will be followed at discharge (or Day 7), Day 30, Day 90, and Day 180. Antihypertensive medications may be adjusted after 90 days according to a predefined protocol based on blood pressure response. Efficacy will be assessed by changes in office and 24-hour ambulatory blood pressure, as well as changes in medication burden. Safety will be monitored by tracking the incidence of Major Adverse Events (MAE), procedure-related complications, and changes in renal function throughout the 180-day follow-up period.",[42],{"label":43,"type":44,"description":45,"interventionNames":46},"Laparoscopic Adventitial RDN","EXPERIMENTAL","Participants will undergo a 28-day run-in period on a standardized antihypertensive medication regimen. Following this period, all participants will receive the investigational treatment, which is a laparoscopic renal artery adventitial denervation procedure. Participants will be followed for 180 days post-procedure",[47],"Device: Renal Artery Radiofrequency Ablation Clamp",[49],{"type":50,"name":51,"description":52,"armGroupLabels":53,"otherNames":33},"DEVICE","Renal Artery Radiofrequency Ablation Clamp","This device is a clamp used during a laparoscopic surgical procedure. It is placed on the external surface (adventitia) of the renal artery and is connected to a radiofrequency generator. It delivers targeted radiofrequency energy to ablate the renal sympathetic nerves.",[43],[55],{"name":56,"role":57,"phone":58,"phoneExt":33,"email":59},"Chuanyu Gao, MD, Phd","CONTACT","13937165590","gaocy6208@163.com",[61],{"facility":62,"status":33,"city":63,"state":64,"zip":33,"country":65,"countryCode":66,"cosmosGeoPoint":67,"geoPoint":72,"contacts":73},"Fuwai Huazhong Cardiovascular Hospital","Zhengzhou","Henan","China","CN",{"type":68,"coordinates":69},"Point",[70,71],113.64861,34.75778,{"lat":71,"lon":70},[74],{"name":75,"role":57,"phone":58,"phoneExt":33,"email":59},"Chuanyu Gao, MD，Phd",{"type":77,"investigatorFullName":78,"investigatorTitle":79,"investigatorAffiliation":5,"oldNameTitle":33,"oldOrganization":33},"PRINCIPAL_INVESTIGATOR","Chuanyu Gao","Professor",[81,84],{"name":82,"class":83},"Hunan Ept Medical Co., Ltd.","UNKNOWN",{"name":85,"class":83},"Shanghai Hongtong Industrial Co., Ltd.","100601310",false,"NCT07108829","Laparoscopic Adventitial Renal Denervation (RDN) for Refractory Hypertension","First-in-Man Clinical Study to Evaluate the Safety and Efficacy of Renal Artery Radiofrequency Ablation Clamp, Radiofrequency Ablation Generator for the Adjunctive Treatment of Refractory Hypertension and Drug-Intolerant Hypertension","Inclusion Criteria:\n\nAge ≥18 years and ≤65 years, any sex.\n\nDiagnosed with primary hypertension.\n\nHistory of hypertension for at least 6 months.\n\nBlood pressure meets the following two conditions:\n\nOffice systolic blood pressure ≥140mmHg and ≤180mmHg, and office diastolic blood pressure ≥90mmHg. If not taking a beta-blocker, resting heart rate must be ≥70bpm.\n\n24-hour ambulatory blood pressure measurement shows an average systolic pressure ≥130mmHg or a daytime average systolic pressure ≥135mmHg.\n\nHas a history of antihypertensive medication use within the last 6 months with uncontrolled blood pressure. Before enrollment, must undergo at least 28 days of a standardized medication regimen (including a diuretic and at least three drugs in total) with ≥80% compliance, while office SBP remains ≥140mmHg and ≤180mmHg, and office DBP remains ≥90mmHg.\n\nPatient is willing and able to comply with follow-up requirements and has signed the informed consent form.\n\nExclusion Criteria:\n\nSecondary hypertension.\n\nTarget renal artery anatomy is unsuitable, including:\n\nRenal artery diameter \\>9mm or \\\u003C4mm.\n\nMultiple renal arteries.\n\nSevere calcification, stenosis \\>50%, malformation, fibromuscular dysplasia, or aneurysm in either renal artery.\n\nHistory of renal artery intervention (e.g., balloon angioplasty or stenting).\n\nUnsuitable for laparoscopic surgery via the retroperitoneal approach, including prior retroperitoneal surgery, retroperitoneal fibrosis, or severe obesity (BMI \\> 40 kg\u002Fm²).\n\nHistory of kidney transplant or severe renal impairment (eGFR \\\u003C 45 mL\u002Fmin\u002F1.73m²).\n\nHospitalization for a hypertensive crisis within the past year.\n\nSevere liver dysfunction (ALT or AST \\> 3 times the upper limit of normal).\n\nType 1 diabetes.\n\nHistory of a cardiovascular event (e.g., myocardial infarction, unstable angina) or cerebrovascular event (e.g., stroke, TIA) within the last 6 months.\n\nPregnancy or planning to become pregnant during the trial.\n\nParticipation in any other investigational drug or device trial within 3 months prior to screening.","ALL","18 Years","65 Years",{"count":96,"type":97},10,"ESTIMATED","INTERVENTIONAL",[35],"This is a first-in-human study to test the safety and effectiveness of a new device-based treatment for high blood pressure that is difficult to control with medicine. This condition is known as refractory hypertension.\n\nThe study will enroll 10 adults aged 18 to 65 whose high blood pressure is not controlled even though they are taking three or more blood pressure medications.\n\nThe treatment involves a new medical device called a Renal Artery Radiofrequency Ablation Clamp. This device is used during a keyhole (laparoscopic) surgery. It works by applying controlled heat (radiofrequency energy) to the outside of the arteries that supply blood to the kidneys. This procedure, known as renal denervation, aims to calm the nerves around these arteries that contribute to high blood pressure.\n\nParticipants who join the study will first be monitored on a standard set of blood pressure medicines to confirm they are eligible. If they qualify, they will undergo the keyhole surgery. After the procedure, participants will be followed for 180 days (about 6 months) and will have several follow-up visits to check their blood pressure and overall health.",[102],"Refractory Hypertension or Drug-intolerant Hypertension",[104,105,106,107,108,109],"Hypertension","Resistant Hypertension","Renal Denervation","Laparoscopic","Radiofrequency Ablation","Sympathetic Nerves","NOT_YET_RECRUITING","2025-07-31",{"date":113,"type":114},"2025-08-07","ACTUAL",{"date":116,"type":97},"2025-08",{"date":118,"type":97},"2026-08",{"name":5,"class":6},1]